Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The agreement could rise to $900 million if key commercial milestones are met
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
Rs. 40 cr buyback, 200% dividend announced
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval was driven by data from the Phase III TULIP-SC trial
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
nSEPIA aims to bring structure to an area long dominated by subjectivity
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The webinar series will showcase next-gen imaging technologies, global expert insights, and hands-on sessions on microscopy innovations
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Subscribe To Our Newsletter & Stay Updated
